Sight Sciences (NASDAQ:SGHT – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.04). Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 44.45%. The business had revenue of $19.27 million during the quarter, compared to analysts’ expectations of $18.34 million. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Sight Sciences Stock Performance
NASDAQ:SGHT opened at $7.75 on Tuesday. The business’s 50-day moving average price is $6.75 and its two-hundred day moving average price is $5.61. Sight Sciences has a twelve month low of $1.04 and a twelve month high of $9.31. The stock has a market cap of $385.64 million, a P/E ratio of -6.92 and a beta of 2.75. The company has a quick ratio of 12.42, a current ratio of 13.01 and a debt-to-equity ratio of 0.31.
Insider Transactions at Sight Sciences
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on SGHT. Piper Sandler restated a “neutral” rating and set a $6.00 price target (up from $5.00) on shares of Sight Sciences in a research report on Friday, May 3rd. Morgan Stanley raised their price target on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Citigroup raised their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research report on Wednesday, July 10th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Sight Sciences currently has a consensus rating of “Hold” and an average target price of $5.70.
Check Out Our Latest Stock Analysis on SGHT
Sight Sciences Company Profile
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Read More
- Five stocks we like better than Sight Sciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Should You Invest in Bonds? Here’s What to Know
- Financial Services Stocks Investing
- Why This Manufacturer is Committing to a Massive Buyback Program
- What Makes a Stock a Good Dividend Stock?
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.